Xoma Royalty Effe (XOMA) Stock
Small biotech company developing and licensing antibody treatments. Here's the price, business snapshot, and what's worth knowing about Xoma Royalty Effe in June 2026.
XOMA Corp (XOMA) is a small-cap biotechnology company best known for developing and licensing antibody-based therapeutics. The firm focuses on identifying promising antibody candidates and advancing them through early clinical development or partnering them with larger biopharma companies for further development and commercialisation. Its market value reflects both potential upside from clinical or licensing milestones and the typical risks faced by development-stage biotechs: regulatory setbacks, trial results, and financing needs. Investors should note XOMA’s reliance on partnerships and milestone-driven revenues, which can make cash flow lumpy. As with any biotech, share-price volatility can be high and outcomes binary; thorough research into the pipeline, recent news, and balance-sheet strength is essential. This summary is general educational information only and not personalised investment advice. Consider whether a small-cap, higher-risk biotech fits your objectives and risk tolerance before investing.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying XOMA's stock with a target price of $64, indicating significant growth potential.
Financial Health
XOMA Corp shows modest revenue and cash flow, but profitability and growth may be a concern.
Dividend
XOMA Corp does not currently pay a dividend, which is common for companies focusing on growth. If you invested $1000, you would receive $0 a year in dividends.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring XOMA
Ozempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketIntellectual Property
These companies own valuable ideas, brands, and inventions that generate reliable, contract-guaranteed income. Their asset-light business models create high-margin revenue streams without the costs of physical production, making them potential profit powerhouses across multiple industries.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Progress or setbacks in trials and licensing milestones can sharply affect valuation, though outcomes are uncertain and can be binary.
Partner Collaborations
XOMA’s strategy relies on partnerships to advance and commercialise candidates, which can reduce development costs but add dependency on third parties.
Small‑cap Volatility
Market moves can be abrupt and driven by news; the stock may suit growth-focused investors who accept higher risk and financing uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
